Stable hemoglobin protein composition

Abstract

The present invention relates to a hemoglobin protein composition comprising biologically active hemoglobin and less than 2% methemoglobin (metHb) wherein the metHb is maintained below 2% after reoxygenation of hemoglobin. Furthermore, hemoglobin protein composition comprising biologically active hemoglobin and less than 25% of charge variants of total oxygenated hemoglobin. Moreover, the present invention also provides an effective concentration of antioxidant more than 5 mM used during heat treatment. The present invention provides pharmaceutically stable composition of hemoglobin. Furthermore, the present invention also provides a process for reducing and/or controlling the formation of metHb, charge variants and inactivation of viral and/or prion during manufacturing of oxygenated hemoglobin. In addition, the invention provides therapeutic use of oxygenated hemoglobin.

Dependencies are inferred from the claim text.